Paxalisib is the leading drug from NASDAQ-listed biotech, Kazia Therapeutics.
Paxalisib is the leading drug from NASDAQ-listed biotech, Kazia Therapeutics.
End of content
No more pages to load
From The Source
- ACN calls for national Standardised Nursing Terminology (SNT) to improve nursing data collection
- Four in 10 residents in Australian Aged Care homes are malnourished, first large scale study reveals – Monash University
- Avive Health launches new mental health hospital in Vic
- Qld Health: Surgery Connect partnership delivering for Queenslanders
- Mental health inpatient services Darwin: 24-bed unit progresses as gov’t defends worst-in-nation label
- DSS: $4.5 million trial to streamline care and support services in Far North Queensland
- First stage of $830 million Liverpool Hospital Redevelopment nearing completion
- Thousands of student nurses in primary care such as GP clinics, schools
- Doctor Robert Byrne disqualified for four years after giving woman drugs and engaging in sex act
- AHHA: Timely data is key for planning the future of oral health workforce
- AHHA Submission to the Draft National Allied Health Workforce Strategy Outline
- DoHAC: Funding for on-site pharmacists in aged care homes